Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

Lancet
John J P KasteleinYale Mitchel

Abstract

Present guidelines emphasise the importance of low concentrations of LDL cholesterol (LDL-C) in patients with familial hypercholesterolaemia. In most patients with the disease, however, these concentrations are not achieved with present treatments, so additional treatment is therefore warranted. Inhibition of cholesteryl ester transfer protein has been shown to reduce LDL-C concentrations in addition to regular statin treatment in patients with hypercholesterolaemia or at high risk of cardiovascular disease. We aimed to investigate the safety and efficacy of anacetrapib, a cholesteryl ester transfer protein inhibitor, in patients with heterozygous familial hypercholesterolaemia. In this multicentre, randomised, double-blind, placebo-controlled, phase 3 study, patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease from 26 lipid clinics across nine countries were eligible. We randomly allocated participants with a computer-generated allocation schedule (2:1; block size...Continue Reading

References

Aug 17, 2001·Current Opinion in Lipidology·P J Barter, K A Rye
Mar 28, 2007·The New England Journal of Medicine·John J P KasteleinUNKNOWN RADIANCE 1 Investigators
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Aug 2, 2008·The New England Journal of Medicine·Daniel Steinberg
Nov 13, 2008·BMJ : British Medical Journal·Jorie VersmissenEric J G Sijbrands
Mar 19, 2009·JAMA : the Journal of the American Medical Association·Marijn C MeuweseUNKNOWN CAPTIVATE Investigators
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
Feb 19, 2013·European Heart Journal·G Kees HovinghAnne M O'Connor
Apr 25, 2013·Expert Opinion on Drug Safety·Kees HovinghJohn Kastelein
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·Robert A HegeleUNKNOWN European Atherosclerosis Society Consensus Panel
Jul 12, 2014·The New England Journal of Medicine·Martin J LandrayJane Armitage

❮ Previous
Next ❯

Citations

Nov 10, 2015·Clinical Therapeutics·Philip J Barter, Kerry-Anne Rye
Nov 10, 2015·Clinical Therapeutics·Traci Turner, Evan A Stein
Jan 1, 2016·Lipids in Health and Disease·Maciej BanachAdrian Covic
Sep 20, 2015·Current Cardiology Reports·Evan A Stein, Frederick J Raal
Mar 26, 2016·The Lancet. Diabetes & Endocrinology·Ezim Ajufo, Daniel J Rader
Nov 26, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Thomas F Whayne
Jan 19, 2016·Current Opinion in Lipidology·Steven E Gryn, Robert A Hegele
Sep 14, 2015·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Juan F Ascaso, Rafael Carmena
May 18, 2016·Pharmacological Reports : PR·Bogusław OkopieńAleksandra Bołdys
Mar 7, 2015·Lancet·Frederick J Raal, Dirk J Blom
May 7, 2016·Current Opinion in Lipidology·Cheryl L Wellington, Ruth Frikke-Schmidt
May 25, 2016·Current Cardiology Reports·Michel Farnier
May 14, 2016·Expert Review of Cardiovascular Therapy·T D FilippatosM Elisaf
Sep 14, 2016·Current Treatment Options in Cardiovascular Medicine·Justin ParizoJoshua W Knowles
Oct 21, 2016·Annals of Neurology·Christopher D AndersonUNKNOWN Global Lipids Genetics Consortium and International Stroke Genetics Consortium
Nov 11, 2016·International Journal of Cardiology·Emily J Callander, Robyn McDermott
Nov 3, 2016·Current Opinion in Lipidology·Belinda A Di BartoloStephen J Nicholls
Nov 22, 2016·Expert Review of Clinical Pharmacology·T D FilippatosM S Elisaf
Nov 18, 2016·Expert Opinion on Drug Metabolism & Toxicology·Claudio Borghi, Arrigo F G Cicero
Apr 4, 2017·Expert Opinion on Investigational Drugs·Gerald H Tomkin, Daphne Owens
Apr 28, 2017·Journal of Agricultural and Food Chemistry·Zhaohui XueXiaohong Kou
Jun 9, 2017·Thrombosis and Haemostasis·Christian WeberEmiel P C van der Vorst
Jun 28, 2017·British Journal of Clinical Pharmacology·Serge Cremers, Jeffrey K Aronson
Sep 30, 2017·Diseases·Theodosios D FilippatosMoses S Elisaf
Sep 9, 2017·Expert Review of Clinical Pharmacology·Georgios Polychronopoulos, Konstantinos Tziomalos
Aug 12, 2016·Journal of Cardiovascular Pharmacology and Therapeutics·Julian Hardy McLainRohit R Arora
Dec 13, 2017·Expert Opinion on Drug Metabolism & Toxicology·Arrigo F G CiceroClaudio Borghi
Apr 22, 2017·Arteriosclerosis, Thrombosis, and Vascular Biology·Jifeng ZhangY Eugene Chen
Jun 15, 2017·Circulation. Cardiovascular Quality and Outcomes·Spencer Phillips HeyAaron S Kesselheim
Jan 3, 2019·Cardiology in Review·Mordechai GrabieWilliam H Frishman
Mar 17, 2019·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Emmanuel Eroume-A EgomVincent M G Maher
Aug 30, 2017·The New England Journal of Medicine·UNKNOWN HPS3/TIMI55–REVEAL Collaborative GroupMartin J Landray
Feb 28, 2020·Journal of the Endocrine Society·José Juan Ceballos-MacíasAlfredo Hernández-Moreno
Mar 24, 2020·Expert Review of Cardiovascular Therapy·Stephen J Nicholls, Kristen Bubb
Feb 12, 2017·Clinical Research in Cardiology Supplements·Anja Vogt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.